Genflow Biosciences Plc (GENFF)
0.0402
0.00 (0.00%)
USD |
OTCM |
Jun 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.74M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 174.2% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 19.49 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The company was founded by Eric Leire in 2020 and is headquartered in London, the United Kingdom. |
| URL | http://genflowbio.com |
| Investor Relations URL | N/A |
| HQ State/Province | Greater London |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The company was founded by Eric Leire in 2020 and is headquartered in London, the United Kingdom. |
| URL | http://genflowbio.com |
| Investor Relations URL | N/A |
| HQ State/Province | Greater London |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |